Immune cells take aim at HPV tumors before standard therapy
NCT ID NCT05639972
First seen Mar 03, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study tests whether giving a single dose of specially engineered immune cells (E7 TCR-T cells) before standard treatment (chemoradiation or surgery) can shrink or eliminate tumors in people with advanced HPV-related cancers. About 15 participants will have their own T cells collected, modified to target HPV, and infused back. The goal is to see if this approach is feasible, safe, and improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.